Minocycline
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
Ximino | CAPSULE, EXTENDED RELEASE, ORAL | 45 mg, 90 mg, 135 mg | ||||
Dynacin, Minocin, Vectrin | CAPSULE, ORAL | 50 mg, 100 mg | ||||
Minocin | CAPSULE, ORAL | 75 mg | ||||
Zilxi | FOAM, TOPICAL | 1.5% | ||||
Minocin | POWDER FOR INJECTION, INTRAVENOUS | 100 mg | ||||
Solodyn | TABLET, EXTENDED RELEASE, ORAL | 45 mg, 55 mg, 65 mg, 80 mg | ||||
Solodyn | TABLET, EXTENDED RELEASE, ORAL | 90 mg, 105 mg, 115 mg, 135 mg |
minocycline (Ximino)
minocycline (Minocin)
Oral acne and periodontal indications are non-formulary. If medication needed for non-formulary use, recommend that patient to use own supply.
Minocycline injection is classified as formulary, restricted to Infectious Disease.
Ximino is non formulary with an interchange to generic minocycline.
Zilxi - Inpatients may use home supply. Alternative formulation products are available for inpatient use.
Reviewed: October 26, 2010 (SOLODYN), April 26, 2011 (SOLODYN), 25 March 2015 (Minocin IV), and 23 August 2016 (Minocycline 75 mg), 22 May 2018 (Ximino), Jan 2023 (Zilxi)
Spotlight Minocycline Topical Foam (Zilxi)